Up Close with Epcoritamab
Last Updated: July 24, 2026
Discover more about epcoritamab-bysp (EPKINLY®).
Related Resources:
PQI in Action
PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/09/2025
PQI
PQI: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 05/05/2026
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 09/09/2026
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
PQI
PQI
Patient Education Sheet
Patient Education Sheet
PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal
Last Updated: 10/21/2026
PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease
Last Updated: 10/21/2026
Rusfertide (Mimrylo)
Last Updated: 10/19/2026
Lirafugratinib (Lyrfigtu)
Last Updated: 10/19/2026